



Patent Application  
Attorney Docket No. PC10244A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 18 day of December 2003.

By

(Signature of person mailing)

Andrea E. Dorigo

(Typed or printed name of person)

RECEIVED

DEC 31 2003

TECH CENTER 1606/2800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: R. S. OBACH :

APPLICATION NO.: 09/528,978 : Examiner: S. JIANG

FILING DATE: 03/21/2000 : Group Art Unit: 1617

TITLE: USE OF CYP2D6 INHIBITORS IN :  
COMBINATION THERAPIES

Mail Stop

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: \_\_\_\_\_

12/18/2003

  
\_\_\_\_\_  
Andrea E. Dorigo  
Attorney for Applicant(s)  
Reg. No. 47,532

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733 -1898

RECEIVED

OFFICE  
DEC 24 2003  
PATENT & TRADEMARK OFFICE  
FEDERAL BUREAU OF INVESTIGATION  
U.S. DEPARTMENT OF JUSTICE  
COMMUNICATIONS CENTER 1800/2003

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC10244A										SERIAL NO. 09/528,978									
										APPLICANT R. S. OBACH																			
										FILING DATE March 21, 2000										GROUP 1617									
U.S. PATENT DOCUMENTS																													
EXAMINER INITIAL	DOCUMENT NUMBER										DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE														
	US	5	1	6	6	2	0	7 A	11/24/92	Smith																			
FOREIGN PATENT DOCUMENTS																													
DOCUMENT NUMBER										DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION															
														YES	NO														
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																													
		/	D. Quellet, et al., "Antimicro Agent and Chemo", Vol. 42, No. 12, December 1998, pages 3107-3112.																										
		/	MA Laurent-kenesi, et al., "Br. J. Clin Pharmacol.", PUBMED Abstract: 12959269; December 1993, 36(6) pages 531-8.																										
		/	N. Yasui, et al., "Pharmacogenetics", PUBMED Abstract: 9352572, October 1997, 7(5) pages 369-374.																										
		/	R. C. Halliday, et al., "An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems", Br. J. Clin Pharmacol., Oct. 1995, 40(4), pages 369-378, abstract (PMID: 8554939 (Medline)).																										
		/	S. E. Ball, et al., "Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desimipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2", British Journal of Clinical Pharmacology, Vol. 43, Issue 6, June 1997, pages 619-626, abstract (PMID: 9205822 (Medline)).																										
		/	S. H. Sindrup, et al., "The pharmacogenetics of codeine hypoalgesia", Pharmacogenetics, Vol. 5, Issue 6, December 1995, pages 335-346, abstract (PMID: 8845855 (Medline)).																										
		/	B. A. Sproule, et al., "Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence", Clinical Pharmacokinetics, Vol. 33, Issue 6, December 1997, pages 454-471, abstract (PMID: 9435993 (Medline)).																										
		/	J. B. Gordon, "SSRIs and St John's Wort: possible toxicity?", American Family Physician, March 1, 1998, Vol. 57, Issue 5, pages 950-953, the whole document.																										
		/	Chandra Prakash, et al., "Metabolism and excretion of a new anxiolytic drug candidate, CP-93393, in healthy male volunteers", Drug Metabolism and Disposition, Vol. 26, No. 5, pages 448-455, page 453, column 2-page 454, column 1.																										
		/	J. S. Markowitz, et al., "Effect of St. John's Wort on Cytochrome P-450 2D6 and 3A4 Activity in Healthy Volunteers", Pharmacology Letters, January 21, 2000, Vol. 66, No. 9, pages 133-139, abstract.																										
		/	F. Broly, et al., "Effect of quinidine on the dextromorphan O-demethylase activity of microsomal fractions from human liver", Br. J. Clin Pharmacol., July 1989, 28(1), pages 29-36, abstract (PMID: 2775613 (Medline)).																										
EXAMINER										DATE CONSIDERED																			
S. Jiang																													
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																													